A new preventive strategy for hypoglycemia incorporating added food diet in patients with type 2 diabetes who received sitagliptin therapy

Endocrine Research

Volumn 37, Issue 4, 2012, Pages 175-181

  Meguro, Shu ^a   Sano, Motoaki ^a   Kawai, Toshihide ^a   Matsuhashi, Tomohiro ^a   Mogi, Satoshi ^a   Fukuda, Keiichi ^a   Itoh, Hiroshi ^a   Suzuki, Yoshihiko ^b,c  

^a KEIO UNIVERSITY   (Japan)

^b Hanzoumon Diabetes City Atlas Clinic   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cardiovascular events; Dipeptidyl peptidase 4 inhibitor; Glycemic control; Hemoglobin A1c; Incretin based drug; Sulfonylurea

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA;

ADULT; AGED; BODY WEIGHT; CALORIC INTAKE; DIABETIC DIET; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; DYSGEUSIA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LEG PAIN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EATING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PYRAZINES; SEVERITY OF ILLNESS INDEX; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; TRIAZOLES; WEIGHT GAIN;

EID: 84866896508     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800.2012.662664     Document Type: Review

References (19)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil AW. 10-year follow-up of intensive glucose control in type 2 diabetes.N Engl J Med 2008;359:1577-1589.
3. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes.N Eng J Med 2008;358:2545-2559.
4. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med 2008;358:2560-2572.
5. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes.N Engl J Med 2009;360:129-139.
6. Riddle MC, AmbrosiusWT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-990.
7. Iwamoto Y, Taniguchi T,Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase- 4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010;57:383-394.
8. Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010;12(7):613-622.
9. Horiuchi H. Diet therapy for diabetes mellitus - Diet therapy and its present status. J Jpn Soc Food Nutr 1954;5:426-431. (in Japanese).
10. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 2010;53(6):450-467.
11. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22(6):920-924.
12. Ray KK, Seshasai SR,Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: ameta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772.
13. Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: ameta-analysis of the effect on glycemic control. Diabetes Care 2002;25:1159-1171.
14. Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008;48:592-598.
15. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obesemen. J Clin EndocrinolMetab 2004;89:3055-3061.
16. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetesmellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-745.
17. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q, Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009;11:167-176.
18. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008;10:1047-1056.
19. Aaboe K, Knop FK, Vilsboll T, et al. KATP Channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:603-608.